Company intelligence / Profile preview

Nexus Dx

San Diego, California, United Statesnexus-dx.com ↗

Ownership: Private
Development stage: Other

Overview

Nexus Dx developed and commercialized rapid, near-patient in vitro diagnostic systems based on its proprietary IB10 technology. These systems provided fast and reliable biomarker-based information at the point of care to improve clinical decision-making. Their products were not approved or distributed in the United States or Canada. In November 2011, Samsung acquired Nexus Dx.

Modalities: DeviceDiagnostic testIn vitro diagnostic
Industry: Protein Biomarker Diagnostics

Partnerships

Samsungglobal distributors

Beyond the preview

Go deeper on Nexus Dx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nexus Dx.

Explore the full profile